Genital Neoplasms, Female  >>  Lenvima (lenvatinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lenvima (lenvatinib) / Eisai, Merck (MSD)
NCT01111461 / 2009-016858-41: Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression

Checkmark P2 trial, endometrial
Sep 2012 - Sep 2012: P2 trial, endometrial
Completed
2
133
Europe, US, RoW
Lenvatinib, E7080, Lenvima
Eisai Inc.
Endometrial Cancer
05/12
10/15
NCT03005015: Lenvatinib in Second Line Endometrial Carcinoma

Withdrawn
2
0
Europe
Lenvatinib, Doxorubicin
European Organisation for Research and Treatment of Cancer - EORTC
Endometrial Neoplasms
07/20
 
NCT01133756 / 2009-016050-41: E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Terminated
1/2
7
US
Lenvatinib, Lenvima, E7080, Carboplatin, Gemcitabine
Eisai Inc., PharmaBio Development Inc.
Ovarian Cancer
02/12
09/12

Download Options